Immune-Targeted Therapy Continues to Fall Short in Ovarian Cancer
Kathleen N. Moore, MD, MS, discusses the challenges with utilizing immune-targeted therapy for ovarian cancer, expands on the impact of the tumor microenvironment on the effectiveness of immune checkpoint inhibitors, and details ongoing research with different treatment approaches in ovarian cancer.
Mirvetuximab Soravtansine Positioned as New Standard in Frα+ Platinum-Resistant Ovarian Cancer
Mirvetuximab soravtansine-gynx demonstrated a 35% reduction in the risk of disease progression or death compared with investigator’s choice of chemotherapy in patients with folate receptor alpha-high, platinum-resistant ovarian cancer.
Treatment Landscape Shifts Away From Chemotherapy Toward Targeted Approaches in ALL
November 22nd 2021Novel approaches with highly active, minimally toxic agents are needed to improve upon traditional chemotherapy and possibly eliminate chemotherapy altogether in the treatment of patients with acute lymphoblastic leukemia.
Moore Voices Excitement With VS-6766 Plus Defactinib in Ovarian Cancer
October 7th 2021Dr. Moore discusses the basis for studying the combination of VS-6766 and defactinib in recurrent low-grade serous ovarian cancer, data that has been generated with the combination from the phase 1/2 FRAME trial, and the potential role for the combination in clinical practice.
Dr. Moore on the Role of Mirvetuximab Soravtansine in Ovarian Cancer
March 4th 2020Kathleen Moore, MD, director, Oklahoma TSET Phase I Clinical Trials Program, and associate professor, Section of Gynecologic Oncology, Jim and Christy Everest Endowed Chair in Cancer Research, director, Gynecologic Oncology Fellowship Program, associate director of Clinical Research, and medical director of the Clinical Trials Office, at Stephenson Cancer Center, discusses the role of mirvetuximab soravtansine in platinum-resistant ovarian cancer.
OncLive Welcomes Stephenson Cancer Center to Strategic Alliance Partnership Program
OncLive® and Stephenson Cancer Center, the only comprehensive academic cancer center in Oklahoma, have become partners in raising the standard of cancer care through OncLive's Strategic Alliance Partnership program, OncLive announced.